Ludwig Kiesel

List of Publications by Year
in descending order

153 papers	5,888 citations	66315 42 h-index	88593 70 g-index
180 all docs	180 docs citations	180 times ranked	7477 citing authors

#	Article	IF	Citations
1	Differential Impact of Membrane-Bound and Soluble Forms of the Prognostic Marker Syndecan-1 on the Invasiveness, Migration, Apoptosis, and Proliferation of Cervical Cancer Cells. Frontiers in Oncology, 2022, 12, 803899.	1.3	5
2	Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities. Geburtshilfe Und Frauenheilkunde, 2022, 82, 181-205.	0.8	8
3	Resveratrol impairs cellular mechanisms associated with the pathogenesis of endometriosis. Reproductive BioMedicine Online, 2022, 44, 976-990.	1.1	10
4	Impact of Musashi-1 and Musashi-2 Double Knockdown on Notch Signaling and the Pathogenesis of Endometriosis. International Journal of Molecular Sciences, 2022, 23, 2851.	1.8	14
5	The heparan sulphate proteoglycan Syndecanâ€1 (<scp>CD138</scp>) regulates tumour progression in a 3D model of ductal carcinoma in situ of the breast. IUBMB Life, 2022, 74, 955-968.	1.5	5
6	The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis. International Journal of Molecular Sciences, 2022, 23, 5793.	1.8	9
7	Endometriosis â€“ how should we classify?. Gynecological Endocrinology, 2022, 38, 449-449.	0.7	0
8	The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3399-3419.	1.2	4
9	Management of urinary incontinence in postmenopausal women: An EMAS clinical guide. Maturitas, 2021, 143, 223-230.	1.0	27
10	Prognostic significance of hedgehog signaling networkâ€related gene expression in breast cancer patients. Journal of Cellular Biochemistry, 2021, 122, 577-597.	1.2	14
11	Collagen I triggers directional migration, invasion and matrix remodeling of stroma cells in a 3D spheroid model of endometriosis. Scientific Reports, 2021, 11, 4115.	1.6	33
12	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Tj ETQq0 0 0 rgBT /Overlock 1	0.8	21
13	Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes. Cancers, 2021, 13, 2318.	1.7	17
14	A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	0.8	19
15	microRNAâ€140â€3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecanâ€4. Journal of Cellular Biochemistry, 2021, 122, 1491-1505.	1.2	12
16	Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas, 2021, 148, 55-61.	1.0	35
17	Knockdown of the prognostic cancer stem cell marker Musashi-1 decreases radio-resistance while enhancing apoptosis in hormone receptor-positive breast cancer cells via p21WAF1/CIP1. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3299-3312.	1.2	17
18	Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement. Maturitas, 2021, 151, 55-62.	1.0	28

#	Article	IF	Citations
19	Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. Maturitas, 2020, 131, 91-101.	1.0	37
20	HS2ST1â€dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior. Cancer Science, 2020, 111, 2907-2922.	1.7	19
21	The Mediterranean diet and menopausal health: An EMAS position statement. Maturitas, 2020, 139, 90-97.	1.0	39
22	The Heparan Sulfate Sulfotransferases HS2ST1 and HS3ST2 Are Novel Regulators of Breast Cancer Stem-Cell Properties. Frontiers in Cell and Developmental Biology, 2020, 8, 559554.	1.8	20
23	miR-142-3p Reduces the Size, Migration, and Contractility of Endometrial and Endometriotic Stromal Cells by Targeting Integrin- and Rho GTPase-Related Pathways That Regulate Cytoskeletal Function. Biomedicines, 2020, 8, 291.	1.4	8
24	Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas, 2020, 135, 82-88.	1.0	51
25	Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 2169.	1.8	26
26	Obesity Epidemicâ€"The Underestimated Risk of Endometrial Cancer. Cancers, 2020, 12, 3860.	1.7	10
27	Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer. Future Oncology, 2019, 15, 1921-1938.	1.1	13
28	Î³â€Secretase inhibition affects viability, apoptosis, and the stem cell phenotype of endometriotic cells. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 1565-1574.	1.3	15
29	Seminal plasma (SP) induces a rapid transforming growth factor beta 1 (TGFÎ²1)â€"independent up-regulation of epithelialâ€"mesenchymal transdifferentiation (EMT) and myofibroblastic metaplasia-markers in endometriotic (EM) and endometrial cells. Archives of Gynecology and Obstetrics, 2019, 299, 173-183.	0.8	10
30	The endometrial stem cell markers notch-1 and numb are associated with endometriosis. Reproductive BioMedicine Online, 2018, 36, 294-301.	1.1	21
31	Reverse engineering of triple-negative breast cancer cells for targeted treatment. Maturitas, 2018, 108, 24-30.	1.0	3
32	Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) â€" Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1089-1109.	0.8	30
33	Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) â€" Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 949-971.	0.8	9
34	Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. The Cochrane Library, 2018, 2018, CD010287.	1.5	88
35	Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No.â€‰015/082, November 2017) â€" Recommendations and Statements for Girls and Women. Geburtshilfe Und Frauenheilkunde, 2018, 78, 567-584.	0.8	56
36	miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. Tumor Biology, 2018, 40, 101042831879188.	0.8	85

#	Article	IF	Citations
37	Effects of black cohosh on estrogen biosynthesis in hippocampus of non-human primates ex vivo in vitro and in human neuroblastoma cells in vitro. Clinical Phytoscience, 2017, 2, .	0.8	3
38	Strain Elastography as a New Method for Assessing Pelvic Floor Biomechanics. Ultrasound in Medicine and Biology, 2017, 43, 868-872.	0.7	22
39	World Endometriosis Society consensus on the classification of endometriosis. Human Reproduction, 2017, 32, 315-324.	0.4	424
40	Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro. Archives of Gynecology and Obstetrics, 2017, 296, 1153-1160.	0.8	8
41	Syndecan-4 expression is upregulated in endometriosis and contributes to an invasive phenotype. Fertility and Sterility, 2016, 106, 378-385.	0.5	13
42	microRNA miR-200b affects proliferation, invasiveness and stemness of endometriotic cells by targeting ZEB1, ZEB2 and KLF4. Reproductive BioMedicine Online, 2016, 32, 434-445.	1.1	76
43	Role of the RANK/RANKL pathway in breast cancer. Maturitas, 2016, 86, 10-16.	1.0	48
44	Longâ€term efficacy of glycerineâ€processed amniotic membrane transplantation in patients with corneal ulcer. Acta Ophthalmologica, 2015, 93, e481-7.	0.6	16
45	miR-142-3p is a novel regulator of cell viability and proinflammatory signalling in endometrial stroma cells. Reproductive BioMedicine Online, 2015, 30, 553-556.	1.1	22
46	The impact of testosterone, tibolone and black cohosh on purified mammary and placental 17Î²-hydroxysteroid dehydrogenase type 1. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 448-457.	2.5	3
47	The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1Î±-/VEGF-signaling. Gynecological Endocrinology, 2015, 31, 160-164.	0.7	22
48	microRNA miR-142-3p Inhibits Breast Cancer Cell Invasiveness by Synchronous Targeting of WASL, Integrin Alpha V, and Additional Cytoskeletal Elements. PLoS ONE, 2015, 10, e0143993.	1.1	89
49	Abstract 3496: Improvement of response to chemotherapy in breast cancer cells by the use of the non-oncologic drug minocycline. , 2015, , .		1
50	Imaging of fetal thymus in pregnant women with rheumatic diseases. Journal of Perinatal Medicine, 2014, 42, 635-639.	0.6	13
51	HS3ST2 modulates breast cancer cell invasiveness via MAP kinaseâ€and Tcf4 (Tcf7l2)â€dependent regulation of protease and cadherin expression. International Journal of Cancer, 2014, 135, 2579-2592.	2.3	58
52	Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. Molecular Cancer, 2014, 13, 174.	7.9	45
53	Abstract 2634: Direct reprogramming of tumor cells: a basis for novel therapeutic approaches. , 2014, , .		0
54	Abstract 920: Secreted frizzled related protein 1 (SFRP1) as potential regulator of chemotherapy response for patients with triple negative breast cancer (TNBC). , 2014, , .		0

#	Article	IF	Citations
55	Abstract LB-101: The antiandrogen drug dutasteride sensitizes triple negative breast cancer cells to chemotherapy via HIF-1Î± / VEGF-signaling. , 2014, , .		0
56	MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an inÂvitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors. Fertility and Sterility, 2013, 99, 1346-1355.e5.	0.5	85
57	Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion. Fertility and Sterility, 2013, 99, 871-881.e1.	0.5	39
58	Serum estradiol and progesterone in the mid-luteal phase predict clinical pregnancy outcome in IVF/ICSI cycles. Gynecological Endocrinology, 2013, 29, 700-703.	0.7	23
59	Syndecanâ€1 modulates Î²â€integrinâ€dependent and interleukinâ€6â€dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS Journal, 2013, 280, 2216-2227.	2.2	94
60	Genomic Profiling in Triple-Negative Breast Cancer. Breast Care, 2013, 8, 408-413.	0.8	24
61	Bridging the Gap - an Update of Translational Research in Breast Cancer. Breast Care, 2013, 8, 397-398.	0.8	0
62	Abstract 5580: Wnt signaling as chemotherapy sensitivity marker of triple negative breast cancer (TNBC).. Cancer Research, 2013, 73, 5580-5580.	0.4	3
63	Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 Signaling. PLoS ONE, 2013, 8, e85737.	1.1	104
64	Abstract LB-211: Targeting triple negative breast cancer by using non-oncologic drug targets.. , 2013, , .		0
65	Fetal myocardial peak systolic strain before and after intrauterine red blood cell transfusion â€“ a tissue Doppler imaging study. Journal of Perinatal Medicine, 2012, 40, 545-550.	0.6	7
66	Impact of testosterone on the expression of organic anion transporting polypeptides (OATP-1A2,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 376-384.	1.0	12
67	Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. European Journal of Cancer, 2012, 48, 2066-2074.	1.3	7
68	Breast cancer molecular subtypes â€“ Modern therapeutic concepts for targeted therapy of a heterogeneous entity. Maturitas, 2012, 73, 288-294.	1.0	20
69	FSH prevents depletion of the resting follicle pool by promoting follicular number and morphology in fresh and cryopreserved primate ovarian tissues following xenografting. Reproductive Biology and Endocrinology, 2012, 10, 98.	1.4	20
70	MicroRNAs and the pathogenesis of endometriosis. Journal of Endometriosis, 2012, 4, 1-16.	1.0	9
71	Evaluation of placental syndecanâ€1 expression in early pregnancy as a predictive fetal factor for pregnancy outcome. Prenatal Diagnosis, 2012, 32, 131-137.	1.1	14
72	Targeting of syndecanâ€1 by microRNA miRâ€10b promotes breast cancer cell motility and invasiveness via a Rhoâ€GTPaseâ€and Eâ€cadherinâ€dependent mechanism. International Journal of Cancer, 2012, 131, E884-96.	2.3	145

#	Article	IF	Citations
73	Abstract 3024: Elucidation of WNT signaling pathway players â€œsFRP-1â€•and â€œTCF7L2â€•as novel potential biomarkers of triple negative breast cancer. , 2012, , .		0
74	Abstract 1198: Conversion of triple negative breast cancer cells into HER2 positive cells - a novel therapeutic approach. , 2012, , .		0
75	Aberrant expression of the pluripotency marker SOX-2 in endometriosis. Fertility and Sterility, 2011, 95, 338-341.	0.5	44
76	Characterization of endometrial mesenchymal stem-like cells obtained by endometrial biopsy during routine diagnostics. Fertility and Sterility, 2011, 95, 423-426.	0.5	112
77	Advanced follicle development in xenografted prepubertal ovarian tissue: the common marmoset as a nonhuman primate model for ovarian tissue transplantation. Fertility and Sterility, 2011, 95, 1428-1434.	0.5	23
78	Spontaneous conception and live birth after gonadotoxic chemotherapy for an aggressive bilateral ovarian Burkitt's lymphoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 158, 362-364.	0.5	2
79	News from the San Antonio Breast Cancer Symposium 2010. Breast Care, 2011, 6, 56-61.	0.8	0
80	mRNA-Expression of ERÎ±, ERÎ², and PR in Clonal Stem Cell Cultures Obtained from Human Endometrial Biopsies. Scientific World Journal, The, 2011, 11, 1762-1769.	0.8	10
81	Perioperative complications in conventional and microsurgical abdominal myomectomy. Archives of Gynecology and Obstetrics, 2011, 284, 137-144.	0.8	15
82	The adult stem cell marker Musashiâ€1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notchâ€1 and p21^{WAF1/CIP1}. International Journal of Cancer, 2011, 129, 2042-2049.	2.3	83
83	Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer. Breast Care, 2011, 6, 1-1.	0.8	18
84	Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Research and Treatment, 2010, 121, 301-309.	1.1	50
85	ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Research and Treatment, 2010, 123, 345-357.	1.1	20
86	Targeting endothelin A receptor enhances antiâ€proliferative and antiâ€invasive effects of the HER2 antibody trastuzumab in HER2â€overexpressing breast cancer cells. International Journal of Cancer, 2010, 127, 696-706.	2.3	18
87	Enoxaparin Improves the Course of Dextran Sodium Sulfate-Induced Colitis in Syndecan-1-Deficient Mice. American Journal of Pathology, 2010, 176, 146-157.	1.9	71
88	miR-145-dependent targeting of Junctional Adhesion Molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene, 2010, 29, 6569-6580.	2.6	197
89	Menstrual abnormalities and predisposition to pregnancy-related hypertensive disorders: a retrospective study. Gynecological Endocrinology, 2010, 26, 445-450.	0.7	26
90	Role of the Heparan Sulfate Proteoglycan Syndecan-1 (CD138) in Delayed-Type Hypersensitivity. Journal of Immunology, 2009, 182, 4985-4993.	0.4	54

#	Article	IF	Citations
91	Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis, 2009, 30, 397-407.	1.3	168
92	Role of syndecan-3 polymorphisms in obesity and female hyperandrogenism. Journal of Molecular Medicine, 2009, 87, 1241-1250.	1.7	12
93	Effect of testosterone on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro. Journal of Steroid Biochemistry and Molecular Biology, 2009, 117, 168-175.	1.2	6
94	Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion. Breast Cancer Research and Treatment, 2008, 108, 175-182.	1.1	22
95	Differential effect of hormone therapy on E1S-sulfatase activity in non-malignant and cancerous breast cells inÂvitro. Breast Cancer Research and Treatment, 2008, 108, 363-374.	1.1	11
96	Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer, 2008, 8, 62.	1.1	73
97	Effects of hormone therapy on estrogen synthesis from E1S in the mammary gland of postmenopausal women. Maturitas, 2008, 59, 163-173.	1.0	2
98	Changes in heparan sulfate are associated with delayed wound repair, altered cell migration, adhesion and contractility in the galactosyltransferase I (ÃŸ4GalT-7) deficient form of Ehlersâ€“Danlos syndrome. Human Molecular Genetics, 2008, 17, 996-1009.	1.4	52
99	Assessment of three-dimensional sonographic features of polycystic ovaries after laparoscopic ovarian electrocautery. Fertility and Sterility, 2007, 88, 894-899.	0.5	14
100	Endocytosis of the dermatan sulfate proteoglycan decorin utilizes multiple pathways and is modulated by epidermal growth factor receptor signaling. Biochimie, 2007, 89, 637-657.	1.3	22
101	Effects of black cohosh on estrogen biosynthesis in normal breast tissue in vitro. Maturitas, 2007, 57, 382-391.	1.0	23
102	An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Research, 2007, 9, R8.	2.2	93
103	Caveolin-1 expression in benign and malignant lesions of the breast. World Journal of Surgical Oncology, 2007, 5, 110.	0.8	24
104	Preterm birth but not mode of delivery is associated with an increased risk of developing inflammatory bowel disease later in life. Inflammatory Bowel Diseases, 2007, 13, 1385-1390.	0.9	52
105	On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Research and Treatment, 2007, 106, 361-369.	1.1	59
106	COX-2 overexpression in peritoneal lesions is correlated with nonmenstrual chronic pelvic pain. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 124, 216-221.	0.5	29
107	Detection of peritoneal endometriotic lesions by autofluorescence laparoscopy. American Journal of Obstetrics and Gynecology, 2006, 195, 949-954.	0.7	34
108	Defective glycosylation of decorin and biglycan, altered collagen structure, and abnormal phenotype of the skin fibroblasts of an Ehlersâ€“Danlos syndrome patient carrying the novel Arg270Cys substitution in galactosyltransferase I (Î²4GalT-7). Journal of Molecular Medicine, 2006, 84, 583-594.	1.7	104

#	Article	IF	Citations
109	Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes and Cancer, 2006, 45, 905-917.	1.5	28
110	Physiological Concept for a Blood Based CFTR Test. Cellular Physiology and Biochemistry, 2006, 17, 29-36.	1.1	20
111	HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 1715-1720.	3.2	249
112	Follicular Fluid High Density Lipoprotein-associated Sphingosine 1-Phosphate Is a Novel Mediator of Ovarian Angiogenesis. Journal of Biological Chemistry, 2006, 281, 5398-5405.	1.6	66
113	Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. British Journal of Cancer, 2006, 95, 347-354.	2.9	104
114	Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Research, 2006, 26, 621-7.	0.5	41
115	Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenetics and Genomics, 2005, 15, 451-456.	0.7	159
116	Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART. Journal of Assisted Reproduction and Genetics, 2005, 22, 277-283.	1.2	9
117	Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Research and Treatment, 2005, 90, 15-23.	1.1	209
118	Overexpression of Endothelin-A-receptor in breast cancer: Regulation by estradiol and cobalt-chloride induced hypoxia. International Journal of Oncology, 2005, 26, 951.	1.4	7
119	Metformin alters insulin signaling and viability of human granulosa cells. Fertility and Sterility, 2005, 84, 1173-1179.	0.5	41
120	Overexpression of Endothelin-A-receptor in breast cancer: regulation by estradiol and cobalt-chloride induced hypoxia. International Journal of Oncology, 2005, 26, 951-60.	1.4	14
121	Endothelin-1-, Endothelin-A-, and Endothelin-B-Receptor Expression Is Correlated with Vascular Endothelial Growth Factor Expression and Angiogenesis in Breast Cancer. Clinical Cancer Research, 2004, 10, 2393-2400.	3.2	103
122	Association of Inhibin B Serum Levels with Parameters of Follicular Response in a Randomized Controlled Trial Comparing GnRH Agonist Versus Antagonist Protocols for Ovarian Hyperstimulation. Journal of Assisted Reproduction and Genetics, 2004, 21, 249-255.	1.2	4
123	Detection of Nonpigmented Endometriotic Lesions with 5-Aminolevulinic Acid-Induced Fluorescence. Journal of Minimally Invasive Gynecology, 2004, 11, 505-510.	1.4	16
124	Endothelin-1, Endothelin-A- and Endothelin-B-receptor expression in preinvasive and invasive breast disease. Oncology Reports, 2004, 11, 791-6.	1.2	20
125	Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. Journal of Cancer Research and Clinical Oncology, 2003, 129, 375-382.	1.2	82
126	Male smokers have a decreased success rate for in vitro fertilization and intracytoplasmic sperm injection. Fertility and Sterility, 2003, 79, 1550-1554.	0.5	134

#	Article	IF	Citations
127	Endometriosis: A genetic disease. Drugs of Today, 2003, 39, 961.	2.4	25
128	Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clinical Cancer Research, 2003, 9, 4125-31.	3.2	91
129	Endobronchial mucosal metastases in breast cancer: a rare metastatic pattern. Lancet Oncology, The, 2002, 3, 702-703.	5.1	1
130	Increased microvessel density in adenomyosis uteri. Fertility and Sterility, 2001, 75, 131-135.	0.5	59
131	Effects of luteinising-hormone-releasing hormone on nervous-system tumours. Lancet, The, 1998, 352, 372-373.	6.3	31
132	Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Research and Treatment, 1993, 25, 37-46.	1.1	62
133	Serum inhibin levels in gonadotrophin stimulated in-vitro fertilization/gamete intra-Fallopian transfer cycles. Human Reproduction, 1992, 7, 1195-1200.	0.4	6
134	Analysis of hormonal changes during combined buserelin/HMG treatment*. Human Reproduction, 1990, 5, 675-681.	0.4	12
135	Action and formation of inositol bisphosphate and inositol trisphosphate in rat anterior pituitary cells. European Journal of Endocrinology, 1990, 123, 459-463.	1.9	2
136	Exogenous action of 5-lipoxygenase by its metabolites on luteinizing hormone release in rat pituitary cells. Molecular and Cellular Endocrinology, 1990, 69, 33-39.	1.6	12
137	Studies on the subcellular mechanisms mediating the negative estradiol effect on GnRH-induced LH-release by rat pituitary cells in culture. European Journal of Endocrinology, 1989, 121, 350-360.	1.9	11
138	Serum Concentration and Urinary Excretion of the Luteinizing Hormone-Releasing Hormone Agonist Buserelin in Patients with Endometriosis. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 1167-1173.	1.8	15
139	Epidermal growth factor stimulates luteinizing hormone and arachidonic acid release in rat pituitary cells. Molecular and Cellular Endocrinology, 1988, 57, 157-162.	1.6	28
140	Arachidonic acid and its lipoxygenase metabolites stimulate prolactin release in superfused pituitary cells. Human Reproduction, 1987, 2, 281-285.	0.4	17
141	Contraceptive progestins and gonadotropin secretion In vitro. The Journal of Steroid Biochemistry, 1987, 27, 995-1002.	1.3	6
142	Stimulation of gonadotropin release by arachidonic acid and its lipoxygenase metabolites in superfused pituitary cells. Life Sciences, 1987, 40, 847-851.	2.0	29
143	Stimulation of luteinizing hormone release by melittin and phospholipase A2 in rat pituitary cells. Molecular and Cellular Endocrinology, 1987, 51, 1-6.	1.6	36
144	Stimulation of Luteinizing Hormone Release and Cyclic Nucleotide Production by Arachidonic Acid in Cultured Pituitary Gonadotrophs. Neuroendocrinology, 1987, 46, 1-9.	1.2	31

#	Article	IF	Citations
145	Top concentrations of dynorphin-like immunoreactivity in fractions of rat anterior pituitary cells enriched in gonadotrophs. Life Sciences, 1986, 38, 2363-2367.	2.0	10
146	Gonadotropin releasing hormone enhances polyphosphoinositide hydrolysis in rat pituitary cells. Biochemical and Biophysical Research Communications, 1986, 134, 861-867.	1.0	61
147	Mechanism of action of gonadotropin releasing hormone: Role of lipoxygenase products of arachidonic acid in luteinizing hormone release. The Journal of Steroid Biochemistry, 1985, 23, 711-717.	1.3	73
148	Regulation of human placental progesterone synthesis in vitro by naturally occurring steroids. The Journal of Steroid Biochemistry, 1985, 22, 657-664.	1.3	16
149	Phosphatidic acid and the calcium-dependent actions of gonadotropin-releasing hormone in pituitary gonadotrophs. Archives of Biochemistry and Biophysics, 1984, 231, 202-210.	1.4	70
150	Inhibition of human placental progesterone synthesis and aromatase activity by synthetic steroidogenic inhibitors in vitro. Fertility and Sterility, 1983, 39, 829-835.	0.5	25
151	Inhibition of human placental progesterone synthesis by danazol in vitro. Fertility and Sterility, 1983, 40, 330-333.	0.5	4
152	The role of prostaglandins, cyclic nucleotides and tricarboxylic acids in the regulation of the human placental 20Î±-hydroxysteroid dehydrogenase in vitro. Steroids, 1982, 40, 99-108.	0.8	6
153	Molecular analysis of the angiogenic status in endometriotic lesions and eutopic endometrium. , 0, 2004, .		0